NeuroPace, Inc. (NPCE): Price and Financial Metrics


NeuroPace, Inc. (NPCE): $5.12

-0.24 (-4.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NPCE Stock Price Chart Interactive Chart >

Price chart for NPCE

NPCE Price/Volume Stats

Current price $5.12 52-week high $25.26
Prev. close $5.36 52-week low $4.61
Day low $5.12 Volume 35,800
Day high $5.70 Avg. volume 67,095
50-day MA $6.31 Dividend yield N/A
200-day MA $10.03 Market Cap 125.98M

NeuroPace, Inc. (NPCE) Company Bio


NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.


NPCE Latest News Stream


Event/Time News Detail
Loading, please wait...

NPCE Latest Social Stream


Loading social stream, please wait...

View Full NPCE Social Stream

Latest NPCE News From Around the Web

Below are the latest news stories about NeuroPace Inc that investors may wish to consider to help them evaluate NPCE as an investment opportunity.

NeuroPace to Report Fourth Quarter and Full Year 2021 Financial Results and Present at the 11th Annual SVB Leerink Global Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the fourth quarter and full year of 2021 after market close on Thursday, March 10, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time. Investors interested in lis

Yahoo | January 27, 2022

NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Revenue

MOUNTAIN VIEW, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2021. Based on available financial information, preliminary unaudited fourth quarter 2021 revenue is expected to be approximately $11.0 million, compared to $10.8 million in the fourth quarter

Yahoo | January 11, 2022

NeuroPace to Present at 40th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced that Mike Favet, CEO, Rebecca Kuhn, CFO and VP of Finance and Administration, and Irina Ridley, General Counsel and Corporate Secretary will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th, 2022, at 8:15 am Pacific Time / 11:15am East

Yahoo | December 16, 2021

NeuroPace, Inc. (NPCE) Q3 2021 Earnings Call Transcript

Image source: The Motley Fool. NeuroPace, Inc. (NASDAQ: NPCE)Q3 2021 Earnings CallNov 10, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon and welcome to NeuroPace's third quarter earnings conference call.

Yahoo | November 11, 2021

NeuroPace Reports Third Quarter 2021 Financial Results

MOUNTAIN VIEW, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended September 30, 2021. Recent Highlights Total revenue of $10.3 million for the third quarter of 2021, representing a 19% decrease over the prior year period in 2020Initial implant revenue of $7.8 million for the third quarter of 2021, representing

Yahoo | November 10, 2021

Read More 'NPCE' Stories Here

NPCE Price Returns

1-mo N/A
3-mo -37.64%
6-mo -49.21%
1-year -78.18%
3-year N/A
5-year N/A
YTD -49.21%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4797 seconds.